Home/Filings/4/0001562180-22-000355
4//SEC Filing

Conway Charles 4

Accession 0001562180-22-000355

CIK 0001689813other

Filed

Jan 6, 7:00 PM ET

Accepted

Jan 7, 9:18 PM ET

Size

17.5 KB

Accession

0001562180-22-000355

Insider Transaction Report

Form 4
Period: 2022-01-06
Conway Charles
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Common Shares

    2022-01-06+3,75023,935 total
  • Tax Payment

    Common Shares

    2022-01-06$123.86/sh1,800$222,94822,135 total
  • Exercise/Conversion

    Restricted Share Unit Award

    2022-01-063,7507,500 total
    Common Shares (3,750 underlying)
  • Award

    Employee Stock Option (right to buy)

    2022-01-07+23,00023,000 total
    Exercise: $128.87Exp: 2032-01-07Common Shares (23,000 underlying)
  • Award

    Restricted Share Unit Award

    2022-01-07+11,50011,500 total
    Common Shares (11,500 underlying)
Footnotes (7)
  • [F1]This balance includes 288 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2021.
  • [F2]No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
  • [F3]Each restricted share unit represents the contingent right to receive one common share of the Issuer.
  • [F4]The reporting person was granted 15,000 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date.
  • [F5]Not applicable.
  • [F6]The shares underlying this option vest in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service with the Issuer at each vesting date.
  • [F7]The reporting person was granted 11,500 restricted share units on January 7, 2022, vesting in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continued service with the Issuer at each vesting date. 100% of these restricted share units are generally subject to settlement in 10 equal annual installments after separation from service.

Issuer

Biohaven Pharmaceutical Holding Co Ltd.

CIK 0001689813

Entity typeother

Related Parties

1
  • filerCIK 0001704256

Filing Metadata

Form type
4
Filed
Jan 6, 7:00 PM ET
Accepted
Jan 7, 9:18 PM ET
Size
17.5 KB